PhD Candidate, Gastroenterology Research Unit, Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
New Zealand Pharmacovigilance Centre, University of Otago, Dunedin, New Zealand.
N Z Med J. 2023 Apr 28;136(1574):82-89. doi: 10.26635/6965.5921.
The therapeutic landscape for treating Inflammatory Bowel Disease (IBD) in Aotearoa New Zealand had remained largely unchanged for about a decade; however, just this year, two further biologic medications became available. In an international context, these medications are not exactly new, and several other highly efficacious, modern medications and treatment paradigms are available overseas but not in New Zealand. Medication adherence (MA), alongside factors including (relaxation of) medicines funding criteria, specialist availability, IBD awareness in primary healthcare etc., contributes to good patient care. Hence, we contend that MA remains of particular importance for New Zealand patients with IBD to derive maximum benefits from the limited therapeutic options available. Moreover, increased research and interventions for promoting MA, in IBD especially, are crucial.
新西兰治疗炎症性肠病（IBD）的治疗方法在过去十年中基本保持不变；然而，就在今年，又有两种生物药物问世。在国际范围内，这些药物并不是全新的，还有其他几种高效、现代的药物和治疗模式在海外可用，但在新西兰不可用。药物依从性（MA）以及包括（放宽）药物资金标准、专家可用性、初级保健中的 IBD 意识等因素，有助于提供良好的患者护理。因此，我们认为 MA 对新西兰 IBD 患者来说仍然特别重要，以便从有限的治疗选择中获得最大的益处。此外，特别是在 IBD 中，增加促进 MA 的研究和干预措施至关重要。
